A TNF-α-ellenes kezelés jelentosége colitis ulcerosában

Translated title of the contribution: Anti-TNF-α therapy in ulcerative colitis

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The most important factors that determine treatment strategy in ulcerative colifts (UC) are disease extent and severity. Orally-topically administered 5-aminosalicylates (5-ASA) remain the treatment of choice in mild-to-moderate UC. in contrast, the treatment of refractory (to steroids, azathioprine or 5-ASA) and fulminant cases is still demanding. New evidence supports a role for infliximab induction and/or maintenance therapy in these subgroup of patients leading to increased remission and decreased colectomy rates. The aim of this paper is to review the rationale for the use of TNF-α inhibitors in the treatment of UC.

Translated title of the contributionAnti-TNF-α therapy in ulcerative colitis
Original languageHungarian
Pages (from-to)921-927
Number of pages7
JournalOrvosi hetilap
Volume149
Issue number20
DOIs
Publication statusPublished - May 18 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Anti-TNF-α therapy in ulcerative colitis'. Together they form a unique fingerprint.

  • Cite this